ADMA Biologics Announces Presentation on Respiratory Viral Infections and New Data on S. Pneumoniae at IDWeek 2020
October 21 2020 - 7:00AM
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an
end-to-end commercial biopharmaceutical company dedicated to
manufacturing, marketing and developing specialty plasma-derived
biologics, today announced an exclusive educational event at IDWeek
2020 on respiratory viral infections, presented by nationally
recognized clinical experts Dr. Michael Ison from Northwestern
University and Dr. Lisa Forbes Satter from Baylor College of
Medicine and Texas Children’s Hospital, as well as new data on
Streptococcus pneumonia in an on-demand poster session.
Educational Event Presentation
Title: Challenges in the Management of Respiratory Viral
Infections in 2020: An Expert Discussion
Session Date: Thursday, October 22,
2020Session Time: 3:00 PM – 3:45 PM
ETSession Location: IDWeek Learning
Lounge
- Michael
G. Ison, MD, MS, Professor of Medicine (Infectious
Diseases) and Surgery (Organ Transplantation) at the Feinberg
School of Medicine at Northwestern University, will present on the
management of respiratory viral infections in immunocompromised
patients and the unique challenges faced today.
- Lisa Forbes
Satter, MD, Assistant Professor of Pediatrics in the
Section of Immunology, Allergy, and Rheumatology at Baylor College
of Medicine and Texas Children’s Hospital, will discuss current
therapeutic modality approaches, and an IVIG product that is
manufactured using patented methodologies for donor screening and
plasma pooling.
Poster Presentation
Title: Kinetics of Post-Vaccination
Seroprotection to S. Pneumoniae for the Immune-Compromised and
Vaccine-Naïve Populations (Mond et al.)Session
Title: Adult VaccinesSession
Date: Wednesday, October 21, 2020Session
Time: On DemandSession
Location: IDWeek Virtual Meeting, Poster
SessionPoster Presentation and
Abstract Number:
911378About ADMA Biologics, Inc. (ADMA)
ADMA Biologics is an end-to-end commercial biopharmaceutical
company dedicated to manufacturing, marketing and developing
specialty plasma-derived biologics for the treatment of
immunodeficient patients at risk for infection and others at risk
for certain infectious diseases. ADMA currently manufactures and
markets three United States Food and Drug Administration (FDA)
approved plasma-derived biologics for the treatment of immune
deficiencies and the prevention of certain infectious diseases:
ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for
the treatment of primary humoral immunodeficiency (PI); BIVIGAM®
(immune globulin intravenous, human) for the treatment of PI; and
NABI-HB® (hepatitis B immune globulin, human) to provide enhanced
immunity against the hepatitis B virus. ADMA manufactures its
immune globulin products at its FDA-licensed plasma fractionation
and purification facility located in Boca Raton, Florida. Through
its ADMA Bio Centers subsidiary, ADMA also operates as an
FDA-approved source plasma collector in the U.S., which provides a
portion of its blood plasma for the manufacture of its products.
ADMA’s mission is to manufacture, market and develop specialty
plasma-derived, human immune globulins targeted to niche patient
populations for the treatment and prevention of certain infectious
diseases and management of immune compromised patient populations
who suffer from an underlying immune deficiency, or who may be
immune compromised for other medical reasons. ADMA has received
U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and
10,259,865 related to certain aspects of its products and product
candidates. For more information, please visit
www.admabiologics.com.
COMPANY CONTACT:Skyler BloomDirector, Investor
Relations and Corporate Strategy | 201-478-5552 |
sbloom@admabiologics.com
INVESTOR RELATIONS CONTACT:Sam MartinManaging
Director, Argot Partners | 212-600-1902
| sam@argotpartners.com
Adma Biologics (NASDAQ:ADMA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Adma Biologics (NASDAQ:ADMA)
Historical Stock Chart
From Sep 2023 to Sep 2024